Chinese Tech Stocks in Focus: WuXi Biologics & Kingdee

WuXi Biologics (2269-hk) & Kingdee (268-hk), the two Chinese tech stocks, have shown promising bullish signals...

Uptrend 2

WuXi Biologics ( Consolidate before Next Rally

WuXi Biologics (, a biopharmaceutical group, released a positive profit alert on July 29, stating that 1H net income is expected to increase by more than 58% on year. The company said "more client projects were added into the Group's pipeline expediting the development and manufacturing of potential treatments related to COVID-19 in support of its global clients". 

As shown on the daily chart, WuXi Biologics' share price has finished a measured move after reaching a high at $193.0 on August 6, suggesting a potential consolidation before the next rally. Bullish investors might consider $152.2 as the nearest support, which is the 61.8% Fibonacci retracement of the rally started from March. The 1st and 2nd resistances are expected to be located at $193.0 and $222.0 respectively. Alternatively, a break below $152.2 may open a path to the next support at $139.7.

Source: TradingView, Gain Capital

Kingdee ( Strong Bullish Momentum

Kingdee (, a software company, issued a profit warning in early July, pointing out that it expects to record a 1H net loss of 200 - 300 million yuan compared with a net profit of 110 million yuan last year. However, its share price showed resilience as investor continue to chase technology stocks.

Kingdee's rally, after breaking above a 2-year consolidation range, remains solid. For the stock to keep its strong bullish momentum, the level at $19.70 is expected to act as the nearest support. The 1st and 2nd resistances are expected to be located at $25.30 and $27.00. Alternatively, losing $19.70 might suggest a deeper price correction to $17.00.

Source: TradingView, Gain Capital

More from Stocks

From time to time, GAIN Capital Australia Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.

As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.